Altman Advisors’s Editas Medicine EDIT Stock Holding History

Altman Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10,860	Closed	-$1.52K	–	74
2018 Q2	$1.52K	Buy	+10,860	New	+$385K	1.4%	43

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Altman Advisors's EDIT Position: Q3 2018 in Review

Altman Advisors sold out of Editas Medicine (EDIT) in Q3 2018, closing a stake of 10,860 shares — an estimated $1.52K sold.

Altman Advisors first reported a position in EDIT in Q2 2018 and held it in 1 quarter. The position peaked at $1.52K in Q2 2018. 199 funds tracked by Wall St. Rank hold EDIT as of Q3 2018.

Altman Advisors reported no remaining Editas Medicine position as of Q3 2018 after selling out during the quarter.
Altman Advisors sold 10,860 Editas Medicine shares in Q3 2018, an estimated $1.52K.
Altman Advisors first reported a position in Editas Medicine in Q2 2018 and held it in 1 quarter.
Altman Advisors's Editas Medicine position peaked at $1.52K in Q2 2018.
199 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2018.

Based on Altman Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.